Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach

Allogene Therapeutics unveils ALLO-329 to target autoimmune disease with allogeneic CAR-T approach
Allogene launches ALLO-329 CAR-T

Allogene Therapeutics introduces ALLO-329, an investigational allogeneic CAR-T therapy intended to transform autoimmune disease treatment.

Powered by the company’s Dagger technology, ALLO-329 aims to reduce or eliminate the need for lymphodepletion, a process that typically precedes cell therapies. This innovation could improve patient experience and broaden access to CAR-T solutions for autoimmune indications. Full clinical data and timeline for regulatory review have not been detailed.

Allogene previously released interim data from its ALPHA3 trial on allogeneic CAR-T therapy for LBCL treatment, highlighting early results in lymphoma patients (see article). The company has also presented new findings on dual CAR-T cells for patients with high-risk multiple myeloma following BCMA therapy (see details). These studies reflect ongoing efforts to expand allogeneic cell therapy options in challenging disease areas.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.